This study aimed to determine if a low dose of ketamine (0.15mg/kg) was just as good (or bad) as a higher dose (0.3mg/kg).
This single ED in Chicago conducted a double-blind RCT that
included adult patients with acute pain (flank, abdo, back, musculoskeletal or
headache) and had a >5 on their initial NRS.
There were several exclusion criteria including patients
that had chronic pain or currently taking opioids. This is arguably the
patient population who would likely be best targeted for ketamine… but I digress.
Ketamine was given as initial therapy without
co-administration of any other analgesics. Yikes!
Oh… and the ketamine was given as a slow IV infusion over 15
minutes (to decrease side effects and increase nursing hassle).
The primary outcome, NRS, was measured at 30 minutes.
They also measured adverse events with the Richmond Agitation Sedation Scale
(RASS) the Side Effect Rating Scale of Dissociative Anaesthetics (SERSDA). (Ketamine
is so special, it even comes with its own measure tool for side effects.)
Results?
98 patients were enrolled and there was no statistical
difference in the primary outcome nor side effects at 30 minutes. The authors
conclude a lower dose is fine.
I disagree.
As a surrogate of patient satisfaction, the authors asked
the patients, “would you take this medication again for similar pain?” An astounding
number said no; 25% vs. 40% in the low and high dose respectively. This is
arguably the most important outcome of this study… patients really didn’t like
this stuff (even when given slowly to minimize side effects).
Let’s face it, we would never use ketamine this way.
It is not first line therapy. Would never use it in isolation. We would target
our patient population differently. And logistically, we probably would not
give an infusion.
So, what can we conclude? Don’t use ketamine this way.
Generally speaking, the hype and enthusiasm for subdissociative ketamine for
pain is ridiculous. Yes, it has its place. But bang-for-buck, it’s a dirty drug;
it doesn’t work that well and comes with many side effects.
Covering:
Lovett S, Reed T, Riggs R, et al. A randomized,
noninferiority, controlled trial of two doses of intravenous subdissociative
ketamine for analgesia in the emergency department. Acad Emerg Med.
2021;00:1-8. DOI:10.1111/acem.14200 [link to article]
No comments:
Post a Comment